164 related articles for article (PubMed ID: 24935596)
1. Significance of ABO-Rh blood groups in response and prognosis in breast cancer patients treated with radiotherapy and chemotherapy.
Cihan YB
Asian Pac J Cancer Prev; 2014; 15(9):4055-60. PubMed ID: 24935596
[TBL] [Abstract][Full Text] [Related]
2. Lack of prognostic value of blood parameters in patients receiving adjuvant radiotherapy for breast cancer.
Cihan YB; Arslan A; Cetindag MF; Mutlu H
Asian Pac J Cancer Prev; 2014; 15(10):4225-31. PubMed ID: 24935375
[TBL] [Abstract][Full Text] [Related]
3. Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer.
Di Lauro L; Vici P; Del Medico P; Laudadio L; Tomao S; Giannarelli D; Pizzuti L; Sergi D; Barba M; Maugeri-Saccà M
Breast Cancer Res Treat; 2013 Aug; 141(1):119-23. PubMed ID: 23982884
[TBL] [Abstract][Full Text] [Related]
4. Clinical Associations with ABO Blood Group and Rhesus Blood Group Status in Patients with Breast Cancer: A Nationwide Retrospective Study of 3,944 Breast Cancer Patients in Turkey.
Akin S; Altundag K
Med Sci Monit; 2018 Jul; 24():4698-4703. PubMed ID: 29981282
[TBL] [Abstract][Full Text] [Related]
5. Identification of patients with hormone receptor-positive breast cancer who need adjuvant tamoxifen therapy for more than 5 years.
Wu CE; Chen SC; Chang HK; Lo YF; Hsueh S; Lin YC
J Formos Med Assoc; 2016 Apr; 115(4):249-56. PubMed ID: 25900861
[TBL] [Abstract][Full Text] [Related]
6. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer.
Conte B; Poggio F; Del Mastro L
Expert Opin Pharmacother; 2017 Sep; 18(13):1357-1362. PubMed ID: 28764603
[TBL] [Abstract][Full Text] [Related]
7. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
Michaud LB; Buzdar AU
Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
[TBL] [Abstract][Full Text] [Related]
8. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma.
Recchia F; Saggio G; Amiconi G; Di Blasio A; Cesta A; Candeloro G; Rea S
Cancer; 2006 Feb; 106(3):514-23. PubMed ID: 16388519
[TBL] [Abstract][Full Text] [Related]
9. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
Tan SH; Wolff AC
Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
[TBL] [Abstract][Full Text] [Related]
10. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.
Jacquet E; Lardy-Cléaud A; Pistilli B; Franck S; Cottu P; Delaloge S; Debled M; Vanlemmens L; Leheurteur M; Guizard AV; Laborde L; Uwer L; Jacot W; Berchery D; Desmoulins I; Ferrero JM; Perrocheau G; Courtinard C; Brain E; Chabaud S; Robain M; Bachelot T
Eur J Cancer; 2018 May; 95():93-101. PubMed ID: 29655061
[TBL] [Abstract][Full Text] [Related]
11. Relationship of body mass index with prognosis in breast cancer patients treated with adjuvant radiotherapy and chemotherapy.
Cihan YB
Asian Pac J Cancer Prev; 2014; 15(10):4233-8. PubMed ID: 24935376
[TBL] [Abstract][Full Text] [Related]
12. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
13. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
[TBL] [Abstract][Full Text] [Related]
14. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
[TBL] [Abstract][Full Text] [Related]
15. Carcinoma of the male breast: a review of adjuvant therapy.
Vinod SK; Pendlebury SC
Australas Radiol; 1999 Feb; 43(1):69-72. PubMed ID: 10901873
[TBL] [Abstract][Full Text] [Related]
16. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
17. Survival improvement in hormone-responsive young breast cancer patients with endocrine therapy.
Yoon TI; Hwang UK; Kim ET; Lee S; Sohn G; Ko BS; Lee JW; Son BH; Kim S; Ahn SH; Kim HJ
Breast Cancer Res Treat; 2017 Sep; 165(2):311-320. PubMed ID: 28601930
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant Ovarian Suppression, High-dose Chemotherapy and Immunotherapy for Premenopausal Patients with High-risk Breast Cancer.
Recchia F; Candeloro G; Rosselli M; Bratta M; Pasta V; D'Orazi V; Fumagalli LA; Rea S
Anticancer Res; 2015 Dec; 35(12):6847-53. PubMed ID: 26637906
[TBL] [Abstract][Full Text] [Related]
20. Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer.
Eggemann H; Altmann U; Costa SD; Ignatov A
J Cancer Res Clin Oncol; 2018 Feb; 144(2):337-341. PubMed ID: 29098396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]